Traders Buy Shares of Eli Lilly And Co (LLY) on Weakness

Traders purchased shares of Eli Lilly And Co (NYSE:LLY) on weakness during trading on Thursday. $153.62 million flowed into the stock on the tick-up and $80.07 million flowed out of the stock on the tick-down, for a money net flow of $73.55 million into the stock. Of all companies tracked, Eli Lilly And Co had the 11th highest net in-flow for the day. Eli Lilly And Co traded down ($1.27) for the day and closed at $115.94

A number of brokerages have recently weighed in on LLY. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Monday, October 8th. Barclays upped their target price on Eli Lilly And Co from $112.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, October 12th. Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the stock a “buy” rating in a research report on Monday, September 17th. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, December 19th. Ten research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and an average target price of $111.50.

The stock has a market cap of $124.16 billion, a P/E ratio of 27.14, a price-to-earnings-growth ratio of 1.68 and a beta of 0.33. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The business’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 EPS. Analysts anticipate that Eli Lilly And Co will post 5.59 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be paid a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a yield of 2.22%. The ex-dividend date of this dividend is Thursday, February 14th. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is 52.57%.

In other Eli Lilly And Co news, SVP Myles O’neill sold 25,000 shares of the company’s stock in a transaction on Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the transaction, the senior vice president now owns 26,562 shares in the company, valued at approximately $2,999,381.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the company’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total value of $9,800,000.00. Following the completion of the transaction, the insider now owns 3,148,647 shares of the company’s stock, valued at approximately $44,081,058. The disclosure for this sale can be found here. Insiders sold a total of 1,702,736 shares of company stock valued at $124,427,811 in the last 90 days. Corporate insiders own 0.11% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Csenge Advisory Group bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth $58,000. Cornerstone Advisors Inc. grew its stake in shares of Eli Lilly And Co by 21.3% during the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after acquiring an additional 136 shares during the period. Welch Group LLC bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth $123,000. Zions Bancorporation bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth $128,000. Finally, Mainstay Capital Management LLC ADV grew its stake in shares of Eli Lilly And Co by 98.0% during the 3rd quarter. Mainstay Capital Management LLC ADV now owns 1,218 shares of the company’s stock worth $131,000 after acquiring an additional 603 shares during the period. Hedge funds and other institutional investors own 77.02% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.thelincolnianonline.com/2019/01/12/traders-buy-shares-of-eli-lilly-and-co-lly-on-weakness.html.

About Eli Lilly And Co (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Book Value Per Share in Stock Trading

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply